Search research articles
Contact Us
Filters
Showing results (121-130 of 198) with videos related to
Page
of 20
Sort By:
Rheumatology and Therapy
|
November 24, 2021
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Philip Conaghan, Stanley Cohen, Gerd Burmester, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
February 5, 2020
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
Alice B Gottlieb, Philip J Mease, Bruce Kirkham, et al.
RMD Open
|
March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
Philip J Mease, Joseph F Merola, Marina Magrey, et al.
RMD Open
|
September 29, 2017
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
Gerd R Burmester, Gurjit S Kaeley, Arthur F Kavanaugh, et al.
The New England Journal of Medicine
|
October 1, 2015
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J Mease, Iain B McInnes, Bruce Kirkham, et al.
RMD Open
|
March 13, 2024
Impact of filgotinib on pain control in the phase 3 FINCH studies
Peter C Taylor, Arthur Kavanaugh, Peter Nash, et al.
ACR Open Rheumatology
|
October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study
Philip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Rheumatology (Oxford, England)
|
October 19, 2017
Remission in psoriatic arthritis-where are we now?
Laura C Coates, Philip G Conaghan, Maria Antonietta D'Agostino, et al.
The Lancet. Rheumatology
|
January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
Iain B McInnes, Philip J Mease, Alan J Kivitz, et al.
The Lancet. Rheumatology
|
January 27, 2024
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Peter Nash, Laura C Coates, Dona Fleishaker, et al.
Page
of 20
Search research articles
Search
Showing results (121-130 of 198) with videos related to
Sort By:
Page
of 20
Rheumatology and Therapy
|
November 24, 2021
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Philip Conaghan, Stanley Cohen, Gerd Burmester, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
February 5, 2020
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
Alice B Gottlieb, Philip J Mease, Bruce Kirkham, et al.
RMD Open
|
March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies
Philip J Mease, Joseph F Merola, Marina Magrey, et al.
RMD Open
|
September 29, 2017
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
Gerd R Burmester, Gurjit S Kaeley, Arthur F Kavanaugh, et al.
The New England Journal of Medicine
|
October 1, 2015
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J Mease, Iain B McInnes, Bruce Kirkham, et al.
RMD Open
|
March 13, 2024
Impact of filgotinib on pain control in the phase 3 FINCH studies
Peter C Taylor, Arthur Kavanaugh, Peter Nash, et al.
ACR Open Rheumatology
|
October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled Study
Philip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Rheumatology (Oxford, England)
|
October 19, 2017
Remission in psoriatic arthritis-where are we now?
Laura C Coates, Philip G Conaghan, Maria Antonietta D'Agostino, et al.
The Lancet. Rheumatology
|
January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
Iain B McInnes, Philip J Mease, Alan J Kivitz, et al.
The Lancet. Rheumatology
|
January 27, 2024
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Peter Nash, Laura C Coates, Dona Fleishaker, et al.
Page
of 20